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ABSTRACT
INTRODUCTION: Diosmin and hesperidin are commonly used flavonoids in the therapy of vascular dis-
eases.
AIM: This study aimed to present an independent evaluation of the market status, quality and biopharma-
ceutical characteristics of diosmin- and hesperidin-containing oral tablet-products (DHCPs) on the Bulgar-
ian market. 
MATERIALS AND METHODS: Seven products, among which medicines (used as reference) and food 
supplements, with sustainable or growing market were selected for the survey: Detralex 500 mg, Phlebodia 
600 mg, Dioket 600 mg, Novarix 650 mg, Asketon 500 mg, Venocode and Dih max 1000 mg. Sales analysis 
for 2016, 2017 and 2018 (year-to-date) was done with the kind support of Iqvia TM. All products were sub-
jected to European Pharmacopoeia (EP) tests for tablet quality - disintegration, resistance to crushing, uni-
formity of mass and uniformity of dosage units. Biopharmaceutical profile regarding tablet drug release 
and dissolution potency was investigated on EP Apparatus 2 (Paddle method). 
RESULTS: Although all products were found to almost fully fulfill the EP criteria, extremely unsatisfying 
drug release was established in all tested media (pH 1,5, pH 4,5 and pH 7,2), reaching not more than 1.6% of 
the labeled content after 24 hours for the best performing products – Novarix and Venocode.  
CONCLUSION: These results were not surprising considering diosmin and hesperidin’s water insolubili-
ty and respective low bioavailability. However, it would be reasonable to approach these two bioactive com-
pounds technologically in preformulation stage in order to improve their solubility and therapeutic potency.
Keywords: diosmin, hesperidin, medicines, food supplements, tablets quality, drug release
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INTRODUCTION
Structure, Sources and Isolation
Diosmin and hesperidin are flavonoids wide-
ly used in the treatment of diseases of microcircula-
tory and vascular origin such as venous insufficien-
cy, varicose veins, hemorrhoids, edemas, post-oper-
ative conditions, etc. Both the flavon (Fig. 1A) and 
the flavanon glycoside (Fig. 1B) possess vasoprotec-
tive and venotonic properties (1-14). Diosmin dif-
fers from hesperidin by a double bond present in the 
structure of the former between C2 and C3 (Fig. 1) 
(1-3). Although both glycosides are naturally occur-
ring in the families of Rutaceae, Lamiaceae, Apiace-
ae, Scrophulariaceae (S. nadosa) (2-10), the industrial 
sector uses semisynthetic diosmin derived from hes-
peridin by a suitable oxidation reaction (I2/pyridine, 
I2/dimethylsulfoxide or other) (1-3,11,15-18). Hesper-
idin is most commonly isolated from dry orange or 
citrus peels (Citrus sinesis, L., Citrus aurantium, L., 
Citrus lemon, L., and other Citrus species) (3,8,10). 
Characteristics
The substances appear as greyish-yellow or light 
yellow hygroscopic powders. They are practically in-
soluble in water and alcohol, soluble in dimethyl sulf-
oxide and dilute solutions of alkali hydroxides (2,19).
Pharmacokinetics
In vivo diosmin and hesperidin are absorbed 
through their aglycone forms - diosmetin and hes-
peretin, respectively, which are products of the in-
testinal flora-mediated metabolism (1,2,7,9,12,13). 
However, the latter are not proven to be active me-
tabolites, as they arise due to biotransformation in 
the gastro-intestinal tract (GIT), but once absorbed, 
further on undergo glucuronidation and biodegra-
dation to fenolic derivatives, while unmetabolized 
forms are not found in plasma (7,9,12). For main me-
tabolites are deemed the 3-O-Glucoronide, 7-O-Glu-
coronides and 3,7-O-Glucoronide conjugates of the 
aglycoons (2,7,12,13). Generally, diosmin and hesper-
idin undergo urine excretion (1,2,7,9,12). The biolog-
ical half-life (t1/2) of diosmetin (or more particularly 
its conjugated forms) is estimated to be 26-43 hours 
(1). Unabsorbed diosmin and hesperidin are elimi-
nated with the feces (1,2). 
Pharmacodynamics
Several mechanisms of action are suggested to 
be responsible for the beneficial effects of the com-
pounds on the vascular system. First, as flavonoid 
representatives, they possess a so-called vitamin P-
action, manifesting in decrease in vascular perme-
ability and increase in capillary sustainability and 
elasticity (6,8,11). The aforementioned effects are hy-
pothesized to be due to interference with catechol-
amine’s metabolism. The flavonoids prolong the ex-
traneuronal presence of noradrenaline and its vaso-
constrictive action by inhibition of the catechol-O-
methyl transferase (COMT-enzyme) and by bind-
ing the free plasma ferric and copper ions in inac-
tive chelate complexes (the ions in question are cat-
alyzers of catecholamine’s oxidation) (20). Another 
theory devotes the P-vitamin action to an inhibito-
ry activity on the hyaluronidase family of enzymes, 
which are responsible for the degradation of hyal-
uronic acid. This extracellular constituent is essen-
tial for vascular health for it is known to strengthen 
the vascular walls by decreasing their permeability 
(21). Next, diosmin and hesperidin have an anti-in-
flammatory effect on the vessels due to prostaglan-
din E2 (PGE2), thromboxane A2 (TxA2) and leu-
kocyte activation, migration and adhesion inhibito-
ry activity (1,2,4,6,11,14,22). The flavonoids also ex-
hibit antioxidant properties owing to their ability to 
inhibit the NO-oxide synthase and block free-radi-
cal chain reactions. This quality of theirs favors the 
vessels’ lumen condition through an antiatherogen-
ic mechanism (1,2,4,5,9,14,22). Last, both flavonoids 
have shown angiotensin-converting enzyme (ACE) 
inhibitory activity, hence they reduce pressure in cir-
culation and this way additionally facilitate the heal-
ing of vascular-related diseases and complications 
(23).  Diosmin and hesperidin are proven to possess 
Fig. 1. Structure of diosmin (A) and hesperidin (B)
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also other effects, unrelated to their vasoactive prop-
erties, such as antineoplastic, antiviral and antifun-
gal (1,24,25). 
Biopharmaceutical Properties
In order to materialize all these desirable effects 
in patients though, diosmin and hesperidin need to 
be bioavailable after oral administration. This is cru-
cial consideration when it comes to these particular 
drugs. Both compounds belong to class IV of the Bi-
opharmaceutical Classification System (BCS) and 
thus possess low water solubility and low permeabili-
ty (2,3,7-9,14,19,26). While the low permeation rate is 
not so critical since the glycosides (if dissolved!) de-
grade to easily absorbable aglycons (diosmetin and 
hesperetin), their water insolubility is a highly lim-
iting factor for pharmaceutical availability, system-
ic absorption and oral bioavailability. Therefore, the 
dosage form formulation, including substance pro-
cessing, adjuvants, type of carrier system, techno-
logical operations etc., has major role in achieving 
optimized therapeutic response. In this regard, the 
use of diosmin and hesperidin in micronized frac-
tion appears to be indispensable for their potency as 
pharmaceuticals (3,7-9,14). The smaller-sized parti-
cles benefit the solubility rate of slightly soluble and 
practically insoluble drugs by enlarging their surface 
area with the dissolvent. However, as mentioned be-
fore, many other technological factors are to be con-
sidered for high pharmaceutical availability. 
AIM
The present study aims to compare the quali-
ty and biopharmaceutical properties of diosmin- and 
hesperidin-containing (or diosmin alone) oral tablet 
products (DHCPs), at the same time making a paral-
lel with their market shares in Bulgaria for the past 
3 years. In the last years, the majority of new com-
peting DHCPs manufacturers register food supple-
ments rather than medicines out of regulatory and 
convenience considerations. As a result, alternatives 
to the conventionally adopted combination of 450 
mg diosmin+50 mg hesperidin or 600 mg diosmin 
tablets, being new combinations with other natural 
vasoprotectors (collagen, hyaluronic acid, escin etc.) 
or new drug concentrations, multiply relatively fast. 
At the same time, medicines as Detralex (450 mg di-
osmin+50 mg hesperidin) and Phlebodia (600 mg di-
osmin) keep holding the major market share on DH-
CPs in Bulgaria as a consequence of their affirmed 
long-standing presence and quality by default (for 
they are a subject of medicine regulation unlike food 
supplements). It is a question, even among the medi-
cal and pharmaceutical society, whether all these al-
ternatives on the market possess the same quality or 
somewhat excel the potency of the referent products. 
In sake of objectivity, it is worth mentioning that the 
flavonoids in question are primarily subject of medi-
cal prescription in Europe, but at the same time pro-
vided mostly as food supplements on the US market 
(12).
Before proceeding to the experimental part ex-
hibition, we would like to emphasize that our assess-
ment was based entirely on in vitro methods and 
prognoses. It does not concern the potential bene-
fits of additional active ingredients in tablets in vivo 
(as hyaluronic acid, escin, collagen, etc.) and regards 
only diosmin/hesperidin content, properties and re-
lease behavior as well as tablet quality.
MATERIALS
Hesperidin standard 97% was purchased from 
Acros Organics Belgium, diosmin:hesperidin 9:1 
commercial mixture micronized (DHM9:1) was 
purchased from Shaanxi Pioneer Biotech Co., Ltd., 
China, sodium hydroxide, di-sodium hydrogen 
phosphate, potassium dihydrogen phosphate, 
sodium chloride were purchased from Thermo 
Fisher Scientific, 0.22 µm pore size PES syringe filter 
– from Filters Fioroni, Spain.
METHODS
Marketing Analysis 
Sales analysis for all products (2016-2018-
year to date (YTD)) was performed with the aid of 
Iqvia TM data base. The sales in packages and BGN 
(summarized for all product variations – for example 
30 tablets package + 60 tablets package + 90 tablets 
package) were presented on pie charts. 
Analytical Method
Diosmin and hesperidin determination was 
performed by UV spectrophotometric method on 
Thermo Scientific Evolution 220 UV/Vis Spec-
trophotometer. Spectra of DHM9:1 and hesperi-
din standard were scanned in 0.25 M NaOH solu-
tions. Absorption maxima were found at 267 nm for 
DHM9:1 and at 283 nm for pure hesperidin (Fig. 2A 
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and B). Standard calibration curves of DHM9:1 and 
hesperidin were built in 0.25 M NaOH in concentra-
tion range of 1-50 mg/L, for each at both wavelengths 
(WL) in order to establish: 1) whether the presence of 
hesperidin will affect linearity for diosmin at 267 nm 
when in mixture 9:1; 2) whether the standard solu-
tions of hesperidin will show reliable linearity in ab-
sorbability at 267 nm, even if  the absorption maxi-
ma of the compound is found at 283 nm; 3) accord-
ingly, whether diosmin and hesperidin can be deter-
mined simultaneously in mixture 9:1 at 267 nm via 
this method, and 4) what would the absorptivity and 
linearity of diosmin alone at 267 nm be, consider-
ing the standard curve of DHM9:1 and hesperidin at 
the same WL. Detailed information about standard 
solutions, concentrations and resulting calibration 
curves is presented in Table 1 and Figure 3.
The aforementioned method was found to be 
suitable for simultaneous determination of diosmin 
and hesperidin for it shows good linearity (R2>0.997) 
and sufficient for the purpose of this study limit of 
detection (LOD).
Fig. 2. UV spectra of DHM9:1 (A) and hesperidin (B) in 
0.25 M NaOH solution at concentration 25 µg/mL
Standard solutions of 
Hesperidin, mg/L
Standard solutions of 
DHM9:1, mg/L
Concentration of 
Diosmin in standard 
solutions of DHM9:1, 
mg/L
Concentration of 
Hesperidin in standard 
solutions of DHM9:1, 
mg/L
1.00 1.00 0.90 0.10
1.25 1.25 1.13 0.13
1.67 1.67 1.50 0.17
2.50 2.50 2.25 0.25
5.00 5.00 4.50 0.50
9.00 10.00 9.00 1.00
10.00 12.50 11.25 1.25
11.25 20.00 18.00 2.00
15.00 25.00 22.50 2.50
22.50 33.33 30.00 3.33
25.00 50.00 45.00 5.00
50.00 100.00 90.00 10.00
Table 1. Standard solutions of DHM91 and hesperidin standard in NaOH 0.25 M
Fig. 3. Standard calibration curves of hesperidin at 267 
nm (A), of hesperidin at 283 nm (B), of DHM9:1 at 267 
nm (C) and diosmin at 267 nm (D)
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Twenty tablets of each DHCP were individually 
weighed on analytical balance. Average mass 
and standard deviation (SD) were determined.
Uniformity of Dosage Units – Mass Variation 
Method
According to the EP recommendations, the test 
for uniformity of dosage units for film-coated tab-
lets (as all tested DHCPs are) was carried out by the 
mass variation method (19). Ten tablets were weighed 
and examined for active substance content. Each tab-
let was pulverized and dispersed in sufficient quan-
tity of 0.25 M NaOH solution. The resulting slurry 
was transferred to a 50 mL volumetric flask and di-
luted up to the mark with 0.25 M NaOH. After ef-
fective homogenization of the mixture, a sample was 
withdrawn, filtrated (0.22 µm pore size PES syringe 
filter), properly diluted and analyzed spectrophoto-
metrically for drug content. Based on the results, ac-
ceptance value (AV) was calculated (19).
Resistance to Crushing
Resistance to crushing of tablets was performed 
on Erweka Tablet Hardness tester (125 series). Ten 
tablets of each product were subjected to the test. Av-
erage hardness was calculated.
Disintegration
Disintegration test for film-coated tablets was 
performed on EP Apparatus A (Erweka Disintegra-
tion tester ZT 220 series). Six tablets of each prod-
uct were subjected to the test in preliminary heated at 
37±2 oC distilled water. Disintegration time was de-
termined as the time needed for all six tablets to dis-
integrate completely. 
In Vitro Dissolution Study
Solubility Study 
Prior to the  study, test for solubility of DHM9:1 
in all selected release media (hydrochloric acid solu-
tion (HAS) pH 1,5, phosphate buffer solution (PBS) 
pH 4,5 and PBS pH 7,2) was carried out. The sub-
stance was added in excess to each solution and left 
under continuous stirring for 24 hours in a tempered 
room (25oC). At the end of the study, sample from the 
supernatant was withdrawn, filtered and analyzed 
for drug concentration. The measured concentration 
was perceived as saturation point for DHM9:1 in the 
given solvent under the above described conditions. 
In regard to the substances poor water solubili-
ty and related problematics in ensuring „sink” condi-
tions during test,  (dissolution test) was performed by 
two methods – Method I (Standard): on EP Appara-
tus 2 - Paddle method (Pharma test dissolution tester 
PT-DT70), and Method II: on flow-through cell re-
sembling setting (Fig. 4). The parameters of the stud-
ies are presented in Table 2.
RESULTS AND DISCUSSION 
In this section, we present the results using a 
code name for each product (Product A, B, C etc.), in 
order to avoid conflict of interests. Where the prod-
Fig. 4. Flow-through cell resembling setting (Method II 
applied for dissolution study): 1. Burette; 2. Pre-heated 
buffer solution (37oC); 3. Dripping of buffer solution into 
a percolator, containing the dosage form (flow-in); 4. Per-
colator, used as release chamber (kept with constant vol-
ume of buffer solution – 50 mL); 5. Test dosage form; 6. 
Filter; 7. Dripping of buffer solution enriched in diosmin 
and hesperidin out of the release chamber into a receiving 
compartment (flow-out); 8. Receiving compartment
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uct is a medicine, index [m] will be found in the upper 
right corner of the initials.
Sales Analysis
Presented on Figure 5 is the sales analysis of 
products from A to G for 2016, 2017 and 2018 YTD. 
As can be seen from the figure, leaders of the mar-
ket are all medicines, whereas the number and total 
share of the food supplements grow with each year, 
but still expectedly, separately they have much fewer 
sales. Another tendency to be noted is the increase in 
the total consumption of DHCPs.
Quality of Tablets
Results of the tests regarding tablet quality are 
summarized in Table 3. All tablets were found to 
comply with the EP criteria for uniformity of mass 
and to possess substantial hardness above 200 N. 
Even though there are no referent values in EP for 
the latter parameter, the hardness of a tablet should 
provide sustainability, at the same time not affect-
ing negatively its disintegration. Since no produc-
er has declared the product to possess modified re-
lease properties, we accepted ≤30 minutes as refer-
ence value for disintegration. Tablets of all products 
were found to disintegrate within 30 minutes, except 
product B - 73 minutes. This observation we attri-
bute to the lack of superdisintegrants in the composi-
tion of Product B, as well as to the excessive hardness 
of the tablet (>300N).  However, knowing the poor 
water solubility of diosmin and hesperidin, slower 
disintegration is highly unlikely to play a crucial role 
in the in vivo performance of the products. Calcula-
tion of AV for uniformity of dosage units showed one 
critical value for Product B and one drastically above 
the EP criteria value (Product C). 























0-1h HAS pH 1,5 900
100 37±0.5 x x
Samples from the 
release media were 
withdrawn at chosen 
times (through 5 µm 
pore size filter) and 
analyzed spectrophoto-
metrically for diosmin 
and hesperidin content. 
Concentration [mg/L] 
was extrapolated to 
[mg] drug released in 
900 mL and % drug 
released was presented 
knowing the  labeled 
drug content in tablets.
1-4h PBS pH 4,5 900








0-1h HAS pH 1,5 50










The buffer solution, 
collected in the receiv-
ing compartiment, was 
analyzed for diosmin 
and hesperidin content 
at chosen times. Drug 
concentration [mg/L] 
was extrapolated to % 
drug released, knowing 
the exact volume of the 
collected buffer at the 
time of the measure-
ment and the labeled 
drug content.
1-4h PBS pH 4,5 50
4-12h PBS pH 7,2 50
Table 2. In vitro drug release tests - parameters of the studies
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Fig. 5. Sales analysis of selected DHCPs for 2016-2018 YTD in packages and BGN
PRODUCT



































Product B 848 0.53 103.20 7.76 16.93 73.00 >300d d
Product C 634 2.39 99.05 12.16 31.64 19.56 218 13
Product D 976 0.56 109.01 4.90 4.24 3.21 >300d d
Product Em 944 0.58 124.22 8.29 -2.83 10.20 256 16
Product Fm 730 1.37 109.99 8.88 12.82 3.30 189 24
Product G 1278 0.65 109.15 5.79 6.25 3.22 >300d d
a SD - standard deviation
b Drug content found in tablets, expressed as percent (%) of the labeled content
c AV was calculated according to the EP recommendations – chapter 2.9.40 Uniformity of dosage units, Mass variation 
d The value of hardness [N] has excelled the apparatus limitations of detection (10-300 N), SD could not be calculated
Table 3. Quality of tablets
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Solubility
In diosmin and hesperidin micronized powder 
9:1 were found: saturate HAS pH 1,5 at 897 µg/L, PBS 
pH 4,5 at 1462 µg/L and PBS pH 7,2 at 2125 µg/L. Ac-
cording to the results obtained and the EP classifica-
tion, DHM9:1 qualify as very slightly soluble in HAS 
pH 1,5 and slightly soluble in PBS pH 4,5 and pH 7,2. 
Drug release profiles of tested DHCPs, obtained 
by Method I are presented on Fig. 6A. Very unsat-
isfying prognosis for pharmaceutical availability for 
all products was established, as the highest percent 
drug released reached no more than 1.6% of the la-
beled content (Product B and C). Fig. 6B on the oth-
er hand, demonstrates the significance of „sink” con-
ditions for the drug release, by presenting the release 
profile of a randomly selected product (Product B) 
obtained by the two described methods - Method I 
(standard method, but „sink” requirements are not 
met according to the drug solubility test) and Meth-
od II („sink” conditions are ensured). Comparison of 
both dissolution profiles of Product B showed differ-
ences in the rate constant of the dissolution process, 
but no substantial difference in the cumulated drug 
released after 12 h; hence, the unsatisfying drug re-
lease of diosmin and hesperidin from the tablets can-
not be attributed to the lack of „sink” conditioning in 
the classical closed dissolution tester system. 
The results obtained in this study we perceive 
as informative in sake of comparison between the se-
lected products. However, further in vivo studies of 
DHCPs and validation of analytical methods for de-
termination of diosmin and hesperidin are needed to 
understand whether the extremely low pharmaceuti-
cal availability corresponds to just as low level of en-
visaged bioavailability. Authors researching this area 
seem to be unanimous about the challenging evalu-
ation of diosmetin plasma concentrations due to the 
necessity of preliminary degradation of conjugat-
ed forms and precise definition of the latter. There-
fore, the available pharmacokinetic data for diosmin 
is inconsistent and highly variable (7, 9, 12). As the 
improvement of diosmin and hesperidin analysis is 
not a primary topic of our study, we rely on sever-
al recent pharmacokinetic reports to cross-check the 
credibility of our findings. For example, Russo et al. 
(2018) compare the pharmacokinetic profile of dios-
min following oral administration of a 500 mg sin-
gle dose µSmin® (a diosmin flavonoid complex) (test) 
and unformulated micronized diosmin (reference). 
The maximum plasma concentrations (Cmax) detect-
ed by the authors are 50.3±22.6 ng/mL and 2.4±1.9 
ng/mL, respectively (7). Assuming the average plas-
ma volume of an adult patient to be 2.75 L, these plas-
ma levels represent 0.06% and 0.003% of the initial 
dose administered (500 mg diosmin correspond to 
246.8 mg aglycone diosmetin). Another study, per-
formed by Silvestro et al. (2013), shows Cmax of dios-
metin following oral intake of 450 mg diosmin to be 
6049.3±5548.6 pg/mL (12). Under the same assump-
tions, this Cmax represents 0.0075% of the initial dose 
administered (450 mg diosmin correspond to 222 
mg diosmetin). In comparison, the predicted val-
ues for pharmaceutical availability in our study vary 
between 0.33-1.57% among the products. Certainly, 
low pharmaceutical availability is a key factor for low 
plasma concentration and low oral bioavailability.  
CONCLUSION
The main problem with DHCPs appears to be 
the very low water solubility of the substances even 
in micronized fraction, leading to unsatisfying phar-
maceutical availability (<1.6%). The need exist of ad-
ditional technological approaches to improve di-
osmin and hesperidin’s in vitro and in vivo perfor-
mance. Such achievement could potentially benefit 
the patients’ therapy and reduce side effects, origi-
nating from the high dose of unabsorbed flavonoids 
(often manifesting as gastro-intestinal disorders). 
Furthermore, it would definitely have a positive eco-
nomic impact. We hope to be able to present a suc-
cessful step in this direction in a future report. 
Figure 6. In vitro drug release of diosmin and hesperi-
din from all DHCPs obtained by Method I (A), compari-
son of release profiles of Product B obtained by Method I 
and II (B)
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